Lee D L, Zhang J, Blanck T J
Department of Anesthesiology, Cornell University Medical College, New York, New York.
Anesthesiology. 1994 Nov;81(5):1212-9. doi: 10.1097/00000542-199411000-00015.
Halothane has been previously shown in vitro to decrease both the inward calcium current in isolated cells and the density of calcium antagonist binding sites in cardiac sarcolemmal membranes prepared from several species, including humans, presumably contributing to the negative inotropic effects seen with volatile anesthetics. In this study we examined whether halothane produced similar changes in calcium channel antagonist binding characteristics ex vivo in an intact perfused heart by using isradipine, a dihydropyridine calcium channel blocker that binds specifically to the alpha 1 subunit of the L-type voltage-dependent calcium channel.
The rat hearts were perfused by the Langendorff method in the presence of halothane and unlabeled isradipine. After the hearts were homogenized and prepared into membranes, a radioligand binding assay was performed and binding curves obtained. Data were analyzed by nonlinear regression analysis of a one-site binding equation and were evaluated by a paired t test.
Halothane protected or inhibited the binding of unlabeled isradipine to calcium channels in a dose-dependent manner such that as the halothane is removed during the membrane preparation process, previously obscured sites were then available for specific binding of the radioligand. The sites that were protected by halothane had a lower affinity for [3H]-isradipine than controls.
In both isolated membranes and the intact heart, halothane changes the availability of calcium channel antagonist binding sites, indicating a change in conformation of the voltage-dependent calcium channel in the presence of anesthetic. This change may result from a direct effect on the protein or from an indirect effect mediated through the membrane lipid bilayer. It also is demonstrated that halothane "protected" channels are probably a modified class of channels compared to those in control tissues as exemplified by the much lower affinity that the protected channels have for [3H]-isradipine. We conclude that a major mechanism by which halothane depresses contractility is mediated through the voltage-dependent calcium channel, and this process results from a conformational change in the channel.
先前的体外研究表明,氟烷可降低分离细胞的内向钙电流以及包括人类在内的多种物种心脏肌膜中钙拮抗剂结合位点的密度,这可能是挥发性麻醉药产生负性肌力作用的原因。在本研究中,我们使用伊拉地平(一种特异性结合L型电压依赖性钙通道α1亚基的二氢吡啶类钙通道阻滞剂),研究氟烷在完整灌注心脏的离体条件下是否会对钙通道拮抗剂结合特性产生类似的变化。
采用Langendorff法在有氟烷和未标记伊拉地平存在的情况下对大鼠心脏进行灌注。心脏匀浆并制成膜后,进行放射性配体结合测定并获得结合曲线。数据通过单点结合方程的非线性回归分析进行分析,并通过配对t检验进行评估。
氟烷以剂量依赖性方式保护或抑制未标记伊拉地平与钙通道的结合,使得在膜制备过程中氟烷被去除后,先前被掩盖的位点可用于放射性配体的特异性结合。被氟烷保护的位点对[3H] - 伊拉地平的亲和力低于对照组。
在分离的膜和完整心脏中,氟烷都会改变钙通道拮抗剂结合位点的可用性,表明在麻醉药存在的情况下电压依赖性钙通道的构象发生了变化。这种变化可能是对蛋白质的直接作用,也可能是通过膜脂双层介导的间接作用。还证明,与对照组织中的通道相比,氟烷“保护”的通道可能是一类经过修饰的通道,例如被保护的通道对[3H] - 伊拉地平的亲和力要低得多。我们得出结论,氟烷降低收缩力的主要机制是通过电压依赖性钙通道介导的,并且这个过程是由通道的构象变化引起的。